124 related articles for article (PubMed ID: 15175945)
1. Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells.
Motomura W; Nagamine M; Tanno S; Sawamukai M; Takahashi N; Kohgo Y; Okumura T
J Gastroenterol; 2004; 39(5):461-8. PubMed ID: 15175945
[TBL] [Abstract][Full Text] [Related]
2. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
3. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
[TBL] [Abstract][Full Text] [Related]
5. Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator.
Farrow B; O'Connor KL; Hashimoto K; Iwamura T; Evers BM
Surgery; 2003 Aug; 134(2):206-12. PubMed ID: 12947319
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
7. Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells.
Kumei S; Motomura W; Yoshizaki T; Takakusaki K; Okumura T
Biochem Biophys Res Commun; 2009 Mar; 380(3):614-9. PubMed ID: 19285010
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
[TBL] [Abstract][Full Text] [Related]
9. The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells.
Yoshimura R; Matsuyama M; Hase T; Tsuchida K; Kuratsukuri K; Kawahito Y; Sano H; Segawa Y; Nakatani T
Int J Mol Med; 2003 Dec; 12(6):861-5. PubMed ID: 14612958
[TBL] [Abstract][Full Text] [Related]
10. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest.
Fujii D; Yoshida K; Tanabe K; Hihara J; Toge T
Anticancer Res; 2004; 24(3a):1409-16. PubMed ID: 15274302
[TBL] [Abstract][Full Text] [Related]
11. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
13. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
14. Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells.
Yoshida K; Tanabe K; Fujii D; Oue N; Yasui W; Toge T
Anticancer Res; 2003; 23(1A):267-73. PubMed ID: 12680223
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone inhibits cell migration, adhesion, and spreading by modulating cytoskeletal rearrangement in human breast cancer cells.
Wang PS; Chou FS; Porchia L; Saji M; Pinzone JJ
Mol Carcinog; 2008 Dec; 47(12):905-15. PubMed ID: 18314876
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells.
Yu HN; Noh EM; Lee YR; Roh SG; Song EK; Han MK; Lee YC; Shim IK; Lee SJ; Jung SH; Kim JS; Youn HJ
Biochem Biophys Res Commun; 2008 Dec; 377(1):242-7. PubMed ID: 18835379
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma ligand prevents the development of chronic pancreatitis through modulating NF-kappaB-dependent proinflammatory cytokine production and pancreatic stellate cell activation.
Hisada S; Shimizu K; Shiratori K; Kobayashi M
Rocz Akad Med Bialymst; 2005; 50():142-7. PubMed ID: 16358954
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
19. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
Motomura W; Takahashi N; Nagamine M; Sawamukai M; Tanno S; Kohgo Y; Okumura T
Int J Cancer; 2004 Jan; 108(1):41-6. PubMed ID: 14618613
[TBL] [Abstract][Full Text] [Related]
20. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
